Order Article Reprints

Kadono Y, Konaka H, Nohara T, Izumi K, Anai S, Fujimoto K, Koguchi T, Ishibashi K, Kawai N, Nakane K, et al. Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study. Cancers. 2023; 15(10):2745. https://doi.org/10.3390/cancers15102745

Kadono, Yoshifumi, Hiroyuki Konaka, Takahiro Nohara, Kouji Izumi, Satoshi Anai, Kiyohide Fujimoto, Tomoyuki Koguchi, Kei Ishibashi, Noriyasu Kawai, Keita Nakane, and et al. 2023. "Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study" Cancers 15, no. 10: 2745. https://doi.org/10.3390/cancers15102745

Kadono, Y., Konaka, H., Nohara, T., Izumi, K., Anai, S., Fujimoto, K., Koguchi, T., Ishibashi, K., Kawai, N., Nakane, K., Iba, A., Masumori, N., Takahara, S., & Mizokami, A. (2023). Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study. Cancers, 15(10), 2745. https://doi.org/10.3390/cancers15102745